Pharmalittle: We’re reading about Medicare plans to negotiate obesity-drug prices, a Novartis 340B lawsuit, and more
Medicare announced plans to negotiate the prices of blockbuster diabetes and weight loss drugs Ozempic and Wegovy
Related Articles
Walleye Tank propels Minnesota healthcare entrepreneurs forward – Mayo Clinic News Network
Thirteen teams took the stage to present their healthcare innovations to a panel of judges and an audience attending in person and online.
Early TAVR for Asymptomatic Severe Aortic Stenosis | NEJM
Whether transcatheter aortic-valve replacement can improve outcomes in patients with asymptomatic severe aortic stenosis has been unclear. Research findings …
These women physicians are tackling issues to improve patient care
Women doctors from innovative health systems across the U.S. are working to transform health care and advance equity in medicine.
CMS faces renewed legal pressure on drug price negotiation program
Teva Pharmaceuticals is suing the Centers for Medicare & Medicaid Services (CMS) for its implementation of the drug price negotiation program under the Inflation Reduction…
Pathogens and planetary change
Nature Reviews Biodiversity – This Review explores the relationship between emerging infectious diseases and biodiversity loss, and how both are connected to global environmental changes…
Will Renaming Some Cancers as Noncancers Hurt or Help?
This Medical News article discusses the ongoing debate about whether the word cancer should be dropped from the names of indolent tumors of the prostate…
Topics in Health Care From MashupMD
Our editors at MashupMD bring you the latest in medicine, health care, and public health from the leading professionals and journals you trust.
A reporter’s JPM notebook: a look ahead for biopharma VC investing
What are biopharma VCs looking to invest in this year? Autoimmune disorders, osteoporosis, and cardiovascular disease are among the areas of interest.
JPM 2025: 10 takeaways from the San Francisco conference
The four-day conference drew roughly 8,000 attendees and featured presentations from more than 500 private and public companies.
EU mulls retaliation after showing China’s bias against foreign device firms
A report found China limits EU-based device manufacturers’ access to its market through policies that favor local suppliers in an “unfair and discriminatory way.”
